Late in 2007, the U.S. Food and Drug Administration (FDA) held a public thought on the possibility of developing a behind-the-counter (BTC) status for drug Late in 2007, the U.S. Food and Drug Administration (FDA) held a public thought on the possibility of developing a behind-the-counter (BTC) status for drug